세계 마이코플라스마 검사 시장 : 규모, 점유율, 동향 분석 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Mycoplasma Testing Market Growth & Trends:

The global mycoplasma testing market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.58% over the forecast period, according to a new report by Grand View Research, Inc. The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Increasing investments in R&D have contributed significantly to the market's revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period

Mycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.

Mycoplasma Testing Market Report Highlights:

• By product, kits and reagents dominated the market, and are anticipated to exhibit the fastest CAGR throughout the forecast period, due to their widespread use in mycoplasma testing
• Ease of conducting the procedure and rapid detection are some of the major advantages offered by the PCR method
• By application, the cell line testing segment held a largest share of 41.65% in 2023, owing to the increase in research projects being done in the field of cell culture
• Mycoplasma contamination can cause alterations in cell culture metabolites and lead to development of toxins. This increases the importance of cell line testing and authentication in the pharmaceutical and biopharmaceutical industries
• North America held the largest share of 39.04% in 2023. This is mostly attributed to the presence of significant market participants, as well as rising R&D spending and federal assistance
• In Asia Pacific, the market is expected to grow at the highest rate in a projected time period driven by factors such as the rising prevalence of target diseases with an aging population, rising awareness and others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Test Segment
    • 1.1.1.2 Service Provider Segment
    • 1.1.1.3 Application Segment
• 1.2 Regional Scope
• 1.3 Estimates and Forecasts Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Increasing R&D investments in life sciences
  • 3.4.2. Rising government support toward pharmaceutical and biotechnology industries
  • 3.4.3. Rising cell culture contamination
  • 3.4.4. Growing demand for the introduction of effective treatment of life-threatening diseases
  • 3.4.5. Increased competition in the market
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of research in cell biology
  • 3.5.2. Slow rate of mycoplasma growth
  • 3.5.3. Possibility of false negative results
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
• 3.7. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Mycoplasma Testing Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Kits & Reagents Market, 2018 - 2030 (USD Million)
  • 4.3.2. PCR Assays
    • 4.3.2.1. PCR Assays Market, 2018 - 2030 (USD Million)
  • 4.3.3. Nucleic Acid Detection Kits
    • 4.3.3.1. Nucleic Acid Detection Kits Market, 2018 - 2030 (USD Million)
  • 4.3.4. Stains
    • 4.3.4.1. Stains Market, 2018 - 2030 (USD Million)
  • 4.3.5. Elimination Kits
    • 4.3.5.1. Elimination Kits Market, 2018 - 2030 (USD Million)
  • 4.3.6. Standards & Controls
    • 4.3.6.1. Standards & Controls Market, 2018 - 2030 (USD Million)
  • 4.3.7. Others
    • 4.3.7.1. Others Market, 2018 - 2030 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Million

Chapter 5. Technology Business Analysis

• 5.1. Mycoplasma Testing Market: Technology Movement Analysis
• 5.2. PCR
  • 5.2.1. PCR Market, 2018 - 2030 (USD Million)
• 5.3. ELISA
  • 5.3.1. ELISA Market, 2018 - 2030 (USD Million)
• 5.4. Direct Assay
  • 5.4.1. Direct Assay Market, 2018 - 2030 (USD Million)
• 5.5. Indirect Assay
  • 5.5.1. Indirect Assay Market, 2018 - 2030 (USD Million)
• 5.6. Microbial Culture Techniques
  • 5.6.1. Microbial Culture Techniques Market, 2018 - 2030 (USD Million)
• 5.7. Enzymatic Methods
  • 5.7.1. Enzymatic Methods Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Mycoplasma Testing Market: Application Movement Analysis
• 6.2. Cell Line Testing
  • 6.2.1. Cell Line Testing Market, 2018 - 2030 (USD Million)
• 6.3. Virus Testing
  • 6.3.1. Virus Testing Market, 2018 - 2030 (USD Million)
• 6.4. End of Production Cells Testing
  • 6.4.1. End of Production Cells Testing Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

• 7.1. Mycoplasma Testing Market: End-use Movement Analysis
• 7.2. Pharmaceutical & Biotechnology Companies
  • 7.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 7.3. Cell Banks
  • 7.3.1. Cell Banks Market, 2018 - 2030 (USD Million)
• 7.4. Contract Research Organizations
  • 7.4.1. Contract Research Organizations Market, 2018 - 2030 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Mycoplasma Testing Market Share By Region, 2023 & 2030
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. U.S. Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.2.4. Canada
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Canada Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.4. UK
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. UK Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.5. France
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. France Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.6. Italy
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Italy Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.7. Spain
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Spain Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Denmark Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Sweden Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Reimbursement Scenario
    • 8.3.10.6. Norway Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.3.11. Russia
    • 8.3.11.1. Key Country Dynamics
    • 8.3.11.2. Target Disease Prevalence
    • 8.3.11.3. Competitive Scenario
    • 8.3.11.4. Regulatory Framework
    • 8.3.11.5. Reimbursement Scenario
    • 8.3.11.6. Russia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. Japan Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. China Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. India Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. South Korea Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Australia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Reimbursement Scenario
    • 8.4.8.6. Thailand Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.4.9. Singapore
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Reimbursement Scenario
    • 8.4.9.6. Singapore Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Brazil Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Mexico Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.5.5. Argentina
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. Reimbursement Scenario
    • 8.5.5.6. Argentina Mycoplasma Testing Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. South Africa Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.4. Saudi Arabia
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. Saudi Arabia Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.5. UAE
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. UAE Mycoplasma Testing Market, 2018 - 2030 (USD Million)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Reimbursement Scenario
    • 8.6.6.6. Kuwait Mycoplasma Testing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1 Company Categorization
• 9.2 Strategy Mapping
  • 9.2.1 New Product Launch
  • 9.2.2 Partnerships
  • 9.2.3 Acquision
  • 9.2.4 Collaboration
  • 9.2.5 Funding
• 9.3 Key Company Market Share Analysis, 2023
• 9.4 Company Profiles
  • 9.4.1 Thermo Fisher Scientific, Inc.
    • 9.4.1.1 Company overview
    • 9.4.1.2 Financial performance
    • 9.4.1.3 Product benchmarking
    • 9.4.1.4 Strategic Initiatives
  • 9.4.2 Merck & Co., Inc.
    • 9.4.2.1 Company overview
    • 9.4.2.2 Financial performance
    • 9.4.2.3 Product benchmarking
    • 9.4.2.4 Strategic Initiatives
  • 9.4.3 Lonza Group AG
    • 9.4.3.1 Company overview
    • 9.4.3.2 Financial performance
    • 9.4.3.3 Product benchmarking
    • 9.4.3.4 Strategic Initiatives
  • 9.4.4 Charles River Laboratories International, Inc.
    • 9.4.4.1 Company overview
    • 9.4.4.2 Product benchmarking
    • 9.4.4.3 Strategic Initiatives
  • 9.4.5 PromoCell GmbH
    • 9.4.5.1 Company overview
    • 9.4.5.2 Financial performance
    • 9.4.5.3 Product benchmarking
    • 9.4.5.4 Strategic Initiatives
  • 9.4.6 Asahi Kasei Medical Co., Ltd.
    • 9.4.6.1 Company overview
    • 9.4.6.2 Financial performance
    • 9.4.6.3 Product benchmarking
    • 9.4.6.4 Strategic Initiatives
  • 9.4.7 Sartorius AG
    • 9.4.7.1 Company overview
    • 9.4.7.2 Financial performance
    • 9.4.7.3 Product benchmarking
    • 9.4.7.4 Strategic Initiatives
  • 9.4.8 InvivoGen
    • 9.4.8.1 Company overview
    • 9.4.8.2 Financial performance
    • 9.4.8.3 Product benchmarking
    • 9.4.8.4 Strategic Initiatives
  • 9.4.9 Eurofins Scientific
    • 9.4.9.1 Company overview
    • 9.4.9.2 Financial performance
    • 9.4.9.3 Product benchmarking
    • 9.4.9.4 Strategic Initiatives
  • 9.4.10 (ATCC) American Type Culture Collection
    • 9.4.10.1 Company overview
    • 9.4.10.2 Financial performance
    • 9.4.10.3 Product benchmarking
    • 9.4.10.4 Strategic Initiatives